

12-1-2011

Epitope characterization of sero-specific monoclonal antibody to Clostridium botulinum neurotoxin type A.

Cindi R Corbett

National Microbiology Laboratory, 1015 Arlington Street, Winnipeg, MB; Department of Medical Microbiology and Infectious Diseases, University of Manitoba

Erin Ballegeer

National Microbiology Laboratory, 1015 Arlington Street, Winnipeg, MB

Kelly A Weedmark

National Microbiology Laboratory, 1015 Arlington Street, Winnipeg, MB

M D Elias

Center for Research on Bioterrorism and Biodefense, Department of Medicine, Jefferson Medical College

Fetweh H Al-Saleem

Follow this and additional works at: <https://jdc.jefferson.edu/medfp>
Center for Research on Bioterrorism and Biodefense, Department of Medicine, Jefferson Medical College
Part of the [Biological Phenomena](#), [Cell Phenomena](#), and [Immunity Commons](#), [Medical Cell Biology](#)

[Commons](#), [Medical Genetics Commons](#), and the [Medical Immunology Commons](#)

See next page for additional authors

Let us know how access to this document benefits you

Recommended Citation

Corbett, Cindi R; Ballegeer, Erin; Weedmark, Kelly A; Elias, M D; Al-Saleem, Fetweh H; Ancharski, Denise M; Simpson, Lance L; and Berry, Jody D, "Epitope characterization of sero-specific monoclonal antibody to Clostridium botulinum neurotoxin type A." (2011). *Department of Medicine Faculty Papers*. Paper 73.
<https://jdc.jefferson.edu/medfp/73>

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Medicine Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors

Cindi R Corbett, Erin Ballegeer, Kelly A Weedmark, M D Elias, Fetweh H Al-Saleem, Denise M Ancharski, Lance L Simpson, and Jody D Berry

Epitope Characterization of Sero-Specific Monoclonal Antibody to *Clostridium botulinum* Neurotoxin Type A

Cindi R. Corbett,^{1,2} Erin Ballegeer,¹ Kelly A. Weedmark,¹ M.D. Elias,³ Fetweh H. Al-Saleem,³
Denise M. Ancharski,³ Lance L. Simpson,³ and Jody D. Berry^{1,2,4}

Botulinum neurotoxins (BoNTs) are extremely potent toxins that can contaminate foods and are a public health concern. Anti-BoNT antibodies have been described that are capable of detecting BoNTs; however there still exists a need for accurate and sensitive detection capabilities for BoNTs. Herein, we describe the characterization of a panel of eight monoclonal antibodies (MAbs) generated to the non-toxic receptor-binding domain of BoNT/A (H_C50/A) developed using a high-throughput screening approach. In two independent hybridoma fusions, two groups of four IgG MAbs were developed against recombinant H_C50/A. Of these eight, only a single MAb, F90G5-3, bound to the whole BoNT/A protein and was characterized further. The F90G5-3 MAb slightly prolonged time to death in an *in vivo* mouse bioassay and was mapped by pepscan to a peptide epitope in the N-terminal subdomain of H_C50/A (H_{CN}25/A) comprising amino acid residues ₉₈₅WTLQDTQEIKQRVVF₉₉₉, an epitope that is highly immunoreactive in humans. Furthermore, we demonstrate that F90G5-3 binds BoNT/A with nanomolar efficiency. Together, our results indicate that F90G5-3 is of potential value as a diagnostic immunoreagent for BoNT/A capture assay development and bio-forensic analysis.

Introduction

THE BOTULINUM NEUROTOXINS (BoNTs) exist as seven distinct serotypes (A-G) and are the causative agents of botulism, a neuroparalytic disease. BoNTs are among the most toxic substances known with an estimated human lethal dose of 1 ng/kg body weight.⁽¹⁾ Naturally occurring botulism transpires from the ingestion of contaminated food or the colonization of the gastrointestinal tract by BoNT-producing clostridia. However, the relative ease of production and the lethality of all the BoNT subtypes has resulted in their inclusion on the Category A Select Agents and Toxins list.⁽¹⁾ Furthermore, mass vaccination against BoNTs is unlikely due to the rarity of the naturally occurring disease, the limited availability and crudeness of the current pentavalent vaccine, and the subsequent inability to use BoNT therapy in vaccines.⁽¹⁾ Neutralizing antibodies have been observed to be protective against toxin challenge. Indeed, polyclonal therapies against BoNT include human immunoglobulin for infant botulism (BoNT serotypes A and B) and equine immunoglobulin for adult botulism (BoNT serotypes A, B, and E).^(1,2) In addition, a despeciated investigational heptavalent antitoxin (HBAT), which contains antibodies to all seven known BoNT serotypes, has recently become available to treat adult botulism.⁽³⁻⁵⁾

The potential severity and lethality of botulism poisoning require that a patient presenting clinical symptoms receive antitoxin in a timely manner, before receiving a definitive diagnosis.^(2,6,7) To date, the gold standard to detect BoNT in clinical samples is the mouse toxicity assay. While both sensitive and specific, this assay takes up to 96 h to complete and requires specialized personnel, facility, and reagent resources.⁽⁸⁾ Due to adverse patient reactions that can occur and batch variation in polyclonal immunoglobulin production, it is desirable to develop rapid methods of diagnosis that permit accurate and sensitive BoNT detection and serotyping capability to ensure the correct course of treatment is initiated as soon as possible. Many efforts have been made to develop alternative, immunologically based assays for BoNT detection in clinical samples, yet these assays are often limited by the availability of high-quality antibodies.⁽⁸⁾

The production of monoclonal antibodies (MAbs) against BoNTs is an excellent choice for several reasons. First, MAbs are consistent between lots. Second, they are well defined and are theoretically in unlimited supply. Mammalian cell lines scale up readily and provide a means to produce clinical grade material. Third, murine hybridomas with bioactivity provide good lead molecules that can be modified by recombinant means for improved bioactivity and/or less immunogenicity, the latter, for example, by simple chimerization strategies.

¹National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.

²Department of Medical Microbiology and Infectious Diseases, ⁴Department of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, Canada.

³Center for Research on Bioterrorism and Biodefense, Department of Medicine, Jefferson Medical College, Philadelphia, Pennsylvania.

Investigation of BoNT structures has provided invaluable information for alternative strategies for antibody development to the BoNTs. All known BoNTs are synthesized as inactive ~150 kDa protoxins composed of three ~50 kDa functional domains. Upon secretion, the protoxin is cleaved by proteases into an active disulfide bond-linked dipeptide consisting of a ~50 kDa light chain and a ~100 kDa heavy chain. The light chain contains the N-terminal catalytic domain, while the heavy chain comprises a ~50 kDa translocation domain (H_N50) and a ~50 kDa C-terminal receptor-binding domain (H_C50). The catalytic domain on the light chain is a zinc-endopeptidase that cleaves target SNARE (soluble NSF attachment protein receptor) complex proteins at the neuromuscular junction, preventing neurotransmitter release. The H_C50 domain contains the receptor-binding site that targets the BoNTs to cholinergic nerve endings where the toxin is internalized via receptor-mediated endocytosis, and the H_N50 translocation domain aids in the intracellular translocation of the enzymatically active light chain into the host cell cytosol.^(9–11)

This H_C50 binding domain (corresponding to residues 873–1295 of BoNT/A) can be further divided into two ~25 kDa subdomains: the N-terminal β -barrel (H_{CN25} subdomain) and the C-terminal β -trefoil fold (H_{CC25} subdomain).^(11,12) BoNTs are proposed to bind to host cell neurons via a two-receptor mechanism, whereas BoNT/A binds to host cell gangliosides followed by specific binding to the glycoprotein receptor SV2 within the synaptic vesicles.^(13–15) The conserved motif H...SXWY...G for ganglioside binding is located within H_{CN25} of BoNT/A and BoNT/B.^(11,16,17) While the specific amino acids for BoNT/A receptor binding have yet to be elucidated, the BoNT/B receptor-binding site is located within its H_{CC25} subdomain, and it is most likely this region that provides the BoNT/A protein receptor site as well.^(14,18) Immunization with the inert H_C50 domains of BoNTs provides a safe and rational approach for MAb development toward BoNTs.

Disruption of BoNT binding to host cell receptors negates toxicity, and the bioactivity of neutralizing MAbs to the H_C50 receptor-binding domain of BoNTs is well-established.^(19–26) A limited number of neutralizing MAbs specific for the BoNT/A H_C50 binding domain, H_C50/A , have been characterized in detail.^(20,24,27,28) Three of these neutralizing antibodies were generated by phage display, of which two were developed from a murine immune library and one was developed from a human library.^(20,27) Several studies on neutralizing MAbs specific for BoNT/A indicate that an oligoclonal mixture of neutralizing antibodies provide a rational design for a potent human therapeutic.^(20,25,26,29,30) Given that each of the seven BoNTs exists as multiple antigenic variants,⁽³¹⁾ one can expect that individual MAbs may have limited *in vivo* protection and pools of well-defined MAbs will be required for optimal protection. There have also been reports of murine MAbs, developed using classical hybridoma technology, which neutralize BoNT/A with high potency.^(25,30) Thus, the potential for development of neutralizing MAbs from murine immune sources to generate lead molecules against BoNT/A and other serotypes clearly exists.

Herein, we describe the development of a panel of MAbs generated using a recombinant non-toxic H_C50 binding domain of BoNT/A and characterize the epitope of MAb F90G5-3, an antibody that binds BoNT/A with nanomolar efficiency

that may serve as an important immunoreagent for diagnostic assay development.

Materials and Methods

Clostridium botulinum neurotoxin immunogens and antigens

Gene segments of BoNT/A (strain 62A; amino acids [aa] 861–1296; accession no. X52066), BoNT/B (strain Okra; aa 853–1291; accession no. M81186), and BoNT/E (strain NCTC 11219; aa 840–1252; accession no. X62683) were used to clone and express recombinant H_C50/A , H_C50/B , and H_C50/E binding domains as previously described.⁽¹⁹⁾ Antibody reactivity with whole BoNT was assessed using available commercial plates (Metabio, Madison, WI) in an ELISA protocol. The whole BoNT toxins correspond to BoNT/A from strain Hall A, BoNT/B from strain Okra B, and BoNT/E from strain Alaska E.

Cloning, expression, and purification of BoNT/A H_C50 subdomains $H_{CN25/A}$ and $H_{CC25/A}$

Gene segments encoding the N-terminal half ($H_{CN25/A}$; aa 865–1100) and the C-terminal half ($H_{CC25/A}$; aa 1077–1296) of the BoNT/A H_C50 receptor-binding domain (strain 62A; aa 865–1296, accession no. M30196) were cloned into the vector pET30^{a+} (Novagen, San Diego, CA), yielding expression plasmids pETHn25A and pETHc25A, respectively. Expression was conducted for 12 h at 20°C in *Escherichia coli* BL21-codon plus(DE3)-RIL (Stratagene, Cedar Creek, TX), grown in Terrific Broth (1.2% peptone, 2.4% yeast extract, 0.94% K_2HPO_4 , 0.22% KH_2PO_4 ; Difco, Sparks, MD), by the addition of 0.5 mM final concentration of IPTG. Bacterial cells were harvested by centrifugation and resuspended in bacterial protein extract reagent (Pierce, Rockford, IL) containing 0.1 mg/mL lysozyme (Sigma, St. Louis, MO), 0.01 mg/mL DNase (Sigma), and a protease inhibitor cocktail (Roche, Indianapolis, IN). The cell suspension was passed twice through a French pressure cell (Thermo Scientific, Ottawa, Canada). A 50 mM sodium phosphate buffer containing 300 mM NaCl, 5 mM imidazole, and 0.1% β -Octyl D-glucopyranoside (β -OG, pH 8.0) was added to the lysed cell suspension and allowed to stand for 30 min followed by centrifugation at 27,000 g for 40 min to remove the precipitate. $H_{CN25/A}$ or $H_{CC25/A}$ were purified from the clarified supernatant by Ni-NTA chromatography (Superflow column, Qiagen, Toronto, Canada). The recombinant proteins were eluted using an imidazole gradient (20–250 mM imidazole in 50 mM sodium phosphate buffer containing 300 mM NaCl and 0.1% β -OG [pH 8.0]). The active fractions (which eluted with ~80 mM imidazole) were pooled and dialyzed against 25 mM sodium phosphate with 0.1% β -OG (pH 6.8). The dialysate was centrifuged at 27,000 g for 30 min to remove the precipitate. This clear supernatant was loaded onto a cation-exchange column containing 4 mL of CM Sepharose Fast Flow (GE-Healthcare Bio-Sciences, Piscataway, NJ) equilibrated with 25 mM sodium phosphate with 0.1% β -OG (pH 6.8). The column was washed with 50 volumes of 25 mM sodium phosphate with 0.1% β -OG (pH 6.8). Bound protein was eluted from the column with a NaCl gradient (5–500 mM NaCl in 25 mM sodium phosphate buffer with 0.1% β -OG [pH 6.8]). The active fractions, which eluted with ~200 mM NaCl, were pooled and dialyzed against PBS with

0.1% β OG. Approximately, 1 to 2 mg of each polypeptide was obtained from 1 L of bacterial culture. The purity of the two polypeptides was confirmed by 10% SDS-PAGE and detected by Western immunoblot using rabbit antisera against BoNT H_C50.

Immunization of mice and generation of hybridoma cell lines

Immunization of mice and generation of the hybridoma cell lines described herein was conducted as described.⁽³²⁾ MABs were first cloned from semi-solid agarose and then clones of interest underwent another 2 rounds of limiting dilution subcloning to ensure they were monoclonal. The MAB isotypes were determined using a commercial dipstick assay (Roche, Indianapolis, IN). The MABs were manually purified from serum-free cell supernatant using HiTrap protein G columns (GE-Healthcare Bio-Sciences), according to the manufacturer's recommendations. MAB and antigen protein concentrations were conducted using BCA reagent assay (Pierce).

ELISA

Reactivity of the antibodies via ELISA was conducted following the standard operating procedures described previously by Corbett and colleagues.⁽³²⁾ For lower limit of detection, H_C50/A was coated in a concentration range from 125 ng to 122 fg. The lower limit of detection was defined at the lowest concentration of antigen where binding was observed with a value at least four times greater than background. For competitive ELISA, 62.5 ng/mL F90G5-3 was incubated with 10 μ g/mL BSA, BoNT/A H_{CC}25/A, or H_{CN}25/A overnight at 4°C with constant end-over-end rotation. The pre-incubated MAB was then diluted 2-fold across a 96-well plate coated with 100 ng/well H_C50/A and the ELISA processed as above. Whole toxin ELISAs were conducted using plates coated with BoNT/A, BoNT/B, or BoNT/E, per the manufacturer's recommendations (Metabolics).

SDS-PAGE and Western immunoblotting

SDS-PAGE gels and Western immunoblots were performed essentially as described previously.⁽³³⁾ Briefly, 2 μ g of H_C50/A, H_C50/B, H_C50/E, H_{CN}25/A, H_{CC}25/A, or irrelevant antigen (bovine serum albumin) were electrophoresed on a 4–20% Criterion Precast polyacrylamide gel (Bio-Rad, Hercules, CA) followed by electrophoretic transfer to Immobilon-P membranes (Millipore, Bedford, MA). The immunoblots were blocked using 0.4% BSA and washed three times with Tris-buffered saline 0.1% Tween-20 (TBS-T). Bound antibody was detected by incubation with HRP-conjugated goat anti-mouse IgG (H+L) antibody (Southern Biotech, Birmingham, AL), diluted 1:1000 with 0.1% skim-0.1% TBS-T, and developed using 4-chloro-1-naphthol substrate (Sigma), according to the manufacturer's instructions.

Surface plasmon resonance

The measurement of the affinity of the MAB for BoNT/A H_C was performed essentially as described previously,^(34–36) using a Biacore 2000 (Biacore, Uppsala, Sweden). BIAevaluation 3.2 software was used to measure and plot the k_{on} and k_{off} values directly, which were then used to calculate the binding affinity (K_D).

Pin peptide epitope mapping

Peptides covering the sequence of BoNT/A H_C were synthesized as 15-mers, overlapping by five residues, coupled to nylon support pins in a 96-well format (Pepscan Systems, Lelystad, Netherlands). All manipulations of the pin peptide assemblies were performed by placing the tips of the pins in the wells of ELISA plates (MaxiSorp, Nalge-Nunc, Rochester, NY). The pins were blocked with 4% BSA/PBS for 1 h at room temperature, followed by incubation with MAB F90G5-3 (diluted in 2% BSA/PBS) for 1 hour at room temperature, and washed three times in 0.9% saline–0.05% Tween-20 with moderate shaking. To detect MAB binding the pins were incubated with secondary antibody and developed as above for




FIG. 1. Reactivity of MABs developed against the H_C50 binding domain of BoNT/A. Anti-H_C50/A MAB reactivity assessed by ELISA, as described previously.⁽³²⁾ One clone, F90G5-3, elicited strong reactivity with whole BoNT/A and was chosen for further characterization.

Western immunoblot. Pins were regenerated according to the manufacturer instructions for re-use.

Mouse protection assay

The functional activity of MAb reactive with whole BoNT/A was assessed using a mouse protection assay (MPA) as previously described.⁽³⁷⁾ The MPA was conducted following the guidelines of the Institutional Animal Use and Care Committee of Thomas Jefferson University (Philadelphia, PA). The MAb-mediated protection was assessed *in vivo* by mixing 50 µg MAb with 5LD₅₀ of BoNT/A toxin, incubating at ambient temperature for 1 h, followed by injection into the tail vein of 25 gm Swiss Webster mice (*n* = 5); this was followed by monitoring percent survival for 5 days.

Results

MAb development and characterization

Spleens from mice immunized with the recombinant BoNT/A H_C50/A fragment were used in two hybridoma fusion procedures. The two fusions resulted in the development of eight anti-H_C50/A MAb producing hybridomas against BoNT/A H_C50 receptor binding domain of BoNT/A⁽³²⁾ (Fig. 1). All of the MAbs, except F90G5-3 (IgG2a/κ), were of the IgG1/κ isotype. Assessment of the BoNT/A reactivity revealed only one MAb, F90G5-3, had strong reactivity with whole BoNT/A neurotoxin, and was therefore chosen for further characterization (Fig. 1). The specificity and reactivity of MAb F90G5-3 were assessed against the H_C50 domains of BoNT/A, BoNT/B, BoNT/E,⁽³²⁾ and the BoNT/A H_C50




FIG. 2. Reactivity and specificity of MAb F90G5-3. (A) ELISA demonstrating concentration-specific reactivity of F90G5-3 with H_C50/A and H_C_{CN}25/A; no reactivity is observed with H_C_{CC}25/A. (B) Lower limit of detection ELISA illustrating that F90G5-3 can detect as low as 8 ng H_C50/A. (C) Western immunoblot depicting specific reactivity of F90G5-3 with denatured H_C50/A (lane 5) and H_C_{CN}25/A (lane 3). No reactivity is observed with irrelevant antigen, BSA (lane 1), H_C_{CC}25/A (lane 2), H_C50/B (lane 6), or H_C50/E (lane 7). Molecular mass markers (kDa), 194, 128, 87, 39, 32, 17, 0.6 (lane 4). (D) Competitive ELISA demonstrating that pre-incubation with H_C_{CN}25/A (■) decreases F90G5-3 reactivity with whole H_C50/A, whereas pre-incubation with H_C_{CC}25/A (▲) or irrelevant protein (BSA, ●) does not decrease reactivity.

subdomains, H_{CN}25/A and H_{CC}25/A (Fig. 2A and C). As we demonstrated previously in a high-throughput method development study, F90G5-3 has excellent serotype specificity for H_C50/A domain with no observed cross-reactivity with H_C50/B or H_C50/E.⁽³²⁾ Indeed, the MAb was reactive with the H_{CN}25/A subdomain and no reactivity was observed for the H_{CC}25/A subdomain via ELISA or denaturing Western immunoblot analysis (Fig. 2A and C, respectively). The lower limit of detection of F90G5-3 for BoNT/A H_C fragment in indirect ELISA was about 8 ng when assayed using ELISA conditions employed within this study (Fig. 2B).

Reactivity of MAb with F90G5-3 with H_{CN}25/A (as demonstrated in ELISA and Western immunoblot analysis) indicates that the antigenic site for F90G5-3 resides in the N-terminal H_{CN}25/A fragment. To further assess the specificity of F90G5-3 for the H_{CN}25/A subdomain, a competition ELISA was conducted. Indeed, decreased reactivity of F90G5-3 for H_C50/A was observed when the MAb was pre-incubated with H_{CN}25/A, and no competition was observed with pre-incubation of F90G5-3 with H_{CC}25/A or irrelevant protein (BSA) (Fig. 2D).

The reactivity of F90G5-3 with denatured H_C50/A and H_{CN}25/A also suggests that the antibody binds to a linear epitope. To further define the linear epitope recognized by F90G5-3, pin peptide mapping was conducted where overlapping pin peptides covering the sequence of BoNT/A H_C50 receptor-binding domain (corresponding to BoNT/A aa residues 865-1296) were utilized. The data showed that F90G5-3 predominantly bound to the peptide epitope corresponding to amino acids ₉₈₅WTLQDTQEIKQRVVF₉₉₉ (Fig. 3), which is found in both the H_C50/A and H_{CN}25/A recombinant proteins.

The MAb F90G5-3 binds to the H_C50/A fragment with nanomolar affinity. Measurement of the affinity of MAb F90G5-3 for H_C50/A was performed via surface plasmon resonance analysis. The *k_{on}* and *k_{off}* rates were 4.8 × 10³/Msec and 1.5 × 10⁻⁴/sec, respectively, and the resultant K_D was 3.5 ± 1.1 nM. This is typical of affinity matured MABs raised to BoNT and other toxins during T cell dependent immune responses, indicating that the H_C50/A immunogen was a suitable surrogate immunogen and is able to portray the native N terminus of the toxin.⁽³⁸⁾




FIG. 3. Analysis of the H_C50/A epitope bound by MAb F90G5-3. (A) Pepscan analysis: pin peptide epitope mapping of MAb F90G5-3. Reactivity of F90G5-3 (▼) and negative control (▲) with overlapping synthetic 15-mer peptides spanning the entire amino acid sequence of H_C50/A. F90G5-3 binds specifically to one linear epitope, ₉₈₅WTLQDTQEIKQRVVF₉₉₉, which is found in both H_C50/A and H_{CN}25/A. (B) Sequence alignment of the residues in BoNT/B and BoNT/E corresponding to residues W985–F999 in BoNT/A, demonstrating the primary amino acid sequence diversity in this region. *, identical residues; :, conserved residues; ., semi-conserved residues. Residues unique to BoNT/A are represented in blocks. (C) Schematic of crystal structure of BoNT/A (reproduced from Lacy and associates⁽¹²⁾ created with Raswin software). Enzymatic (light chain) is represented in yellow, H_N50 translocation domain represented in green, H_{CN}25 in blue, and H_{CC}25 in magenta. The F90G5-3 epitope, residues W985–F999, is highlighted in red. BoNT/A GT1b ganglioside binding residues identified by Rummel and colleagues⁽¹⁶⁾ are depicted in orange space. Residues identified to interact with the neutralizing antibodies CR1 and AR2⁽⁴⁰⁾ are depicted in pink and cyan space fill.




FIG. 4. Reactivity and functional activity of MAb F90G5-3 with whole BoNT. (A) End-point titration of F90G5-3 against BoNT/A, BoNT/B, and BoNT/E assessed via ELISA demonstrating specificity for BoNT/A. Reactivity with BoNT/A (■), BoNT/B (▲), or BoNT/E (▼) is depicted. (B) Functional activity of MAb F90G5-3 assessed via MPA for BoNT/A neutralization. Although there is not complete neutralization of BoNT/A, delayed time to death is significant ($p < 0.005$). F90G5-3 treated mice (▼); mock-treated mice (▲).

The sero-specificity and endpoint ELISA titers were also determined for whole BoNTs. No cross-reactivity with BoNT/B or BoNT/E was observed, and F90G5-3 had an anti-BoNT/A titer of 3.1 ng/mL in whole BoNT/A toxin ELISA (Fig. 4A). The functional activity of MAb F90G5-3 was assessed using the mouse protection assay (MPA). Mice were challenged with 5LD₅₀ of BoNT/A pre-incubated with MAb F90G5-3. Although MAb F90G5-3 was not able to neutralize all toxin activity, as death was observed in the treated mice, F90G5-3 treatment resulted in a slightly increased time to death ($p < 0.005$, Fig. 4B).

Discussion

We used recombinant H_C50/A to develop a MAb to BoNT/A that binds a linear epitope in the H_{CN}25/A subdomain (985WTLQDTQEIKQRVVF₉₉₉) with nanomolar affinity. Moreover, the use of non-toxic H_C50 antigens for the development of MAbs against whole BoNTs provides a safe alternative for the development of BoNT detection reagents. Within this study, only one MAb out of eight was highly reactive with whole BoNT/A and thus selected for further study.

The fact that we were able to develop antibody to this epitope utilizing the H_C50/A receptor-binding domain and selecting for those that cross-react with whole BoNT/A is not surprising, as the epitope is surface exposed within the full-length BoNT/A (Fig. 3C). One can observe slight reactivity in the Pepsan (Fig. 3A) with a second peptide corresponding to amino acids 1195TNASQAGVEKILSAL₁₂₀₉. Given that F90G5-3 is a monoclonal antibody, this reactivity is most likely due to cross-reactivity with similar amino acid residues and thus an artefact of the *in vitro* pepsan assay, as this sequence is located within H_C25/A sub-region of BoNT/A with which F90G5-3 does not specifically react (Fig. 2). Interestingly, comparison of the primary amino acid sequence in the region corresponding to the 985WTLQDTQEIKQRVVF₉₉₉ epitope in

BoNT/A to BoNT/B and BoNT/E reveals that five of 15 residues are identical between all three toxins, whereas paired comparison of BoNT/A with BoNT/B or BoNT/E shows only two of 15 and one of 15 are conserved and semi-conserved between all three BoNTs, respectively (Fig. 3B). Indeed, only six residues are unique within this region in BoNT/A, indicating that BoNT/A residues TQE-K-R are critical for F90G5-3 binding and strongly suggesting that this region is under intense immune or environmental selection pressure.

The modest neutralization of BoNT/A by MAb F90G5-3 demonstrates that interaction with epitope 985WTLQDTQEIKQRVVF₉₉₉ only slightly decreases the functional activity of the neurotoxin. This partially neutralizing epitope lies within the H_{CN}25/A subdomain of H_C50/A, a region with greater primary sequence homology in comparison to the H_{CC}25 subdomain, which is more antigenic and important for host cell ganglioside binding.^(11,16,39) In the schematic representation of BoNT/A, one can observe the residues important for host cell ganglioside receptor binding are located on an adjacent surface to the F90G5-3 epitope (Fig. 3C, orange space fill). The interaction with the host cell gangliosides is the first low affinity binding interaction that brings the toxin in close proximity to the host cells in the dual receptor model of binding.⁽¹⁵⁾ Antibody bound to the F90G5-3 epitope (Fig. 3C, red space fill) may cause steric hindrance to partially occlude the ganglioside-binding site and thus provide an explanation for the delayed time to death observed within this study. While the amino acid residues that interact with the host cell protein receptor have yet to be clearly elucidated, Garcia-Rodriguez and colleagues have recently co-crystallized neutralizing antibody fragments (CR1 and AR2) with BoNT/A, thus identifying critical contact residues for neutralization.⁽⁴⁰⁾ The amino acid residues of BoNT/A identified as the structural binding epitope of neutralizing CR1 are depicted in the pink color space fill, and the residues identified as part of the functional epitopes of both neutralizing MAbs CR1 and AR2 are depicted in the cyan space fill (Fig. 3C).⁽⁴⁰⁾ In this

schematic, it does not appear that the epitope bound by MAb F90G5-3 interferes with these key neutralizing residues.

Most significantly, MAb F90G5-3 was specific for H_C50/A and bound to a linear epitope (985WTLQDTQEIKQRVVF₉₉₉) within the H_{CN}25/A subdomain with nanomolar affinity. A search of the Immune Epitope Database (www.immuneepitope.org) reveals that this minimal epitope has been targeted by antibody responses from other species as a part of longer contiguous regions. Indeed, the epitope has been studied through peptide mapping of polyclonal immune serum raised to the BoNT/A toxin in multiple species.⁽⁴¹⁾ Using a radioimmunoassay, the C10 peptide (BoNT/A residues 981-999) was found to be immunodominant in humans and chickens but recessive in equine and outbred mice. Intriguingly, sera from 24 of 28 cervical dystonia patients treated with BONT/A contained neutralizing antibodies that bound the C10 epitope (residues 981-999).⁽⁴²⁾ The hybridoma F90G5-3 may thus be a rare clone or the polyclonal response in inbred mice may not mirror that observed by Attasi and Dolimbek.⁽⁴¹⁾ While other studies have evaluated the immunogenicity of this discrete region as a part of larger polypeptides, the immunogenicity of this minimal target remains unknown and needs investigation given the empirical nature of protein immunogens. Nevertheless, these data reveal the first minimal MAb epitope 985WTLQDTQEIKQRVVF₉₉₉ to map to this small domain for F90G5-3. Importantly, our findings that MAb F90G5-3 binds to a specific epitope region of BoNT/A with high affinity and that this epitope target is highly immunoreactive in humans indicates that F90G5-3 is of potential value as a diagnostic immunoreagent for BoNT/A capture assay development and bioforensic analysis.

Acknowledgments

This work was supported by the Public Health Agency of Canada, project CRTI 03-0021TD from the Chemical, Biological, Radiological, Nuclear and Explosive (CBRNE) Research and Technology Initiative (J.D.B.) and a National Institute of Allergy and Infectious Diseases contract (N01-AI-30050 to L.L.S.). Thanks are extended to M. Garbutt, the staff of the Monoclonal Antibody Section, and Emerging Bacterial Pathogens Division at the National Microbiology Laboratory for their expert technical help.

Author Disclosure Statement

The views and opinions expressed herein are those of the authors only, and do not necessarily represent the views and opinions of the Public Health Agency of Canada, the Government of Canada, or the CRTI.

The authors have no financial interests to disclose.

References

1. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, Lillibridge S, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Swerdlow DL, and Tonat K: Botulinum toxin as a biological weapon: medical and public health management. *J Am Med Assoc* 2001;285(8):1059-1070.
2. Arnon SS, Schechter R, Maslanka SE, Jewell NP, and Hatheway CL: Human botulism immune globulin for the

- treatment of infant botulism. *New Engl J Med* 2006;354(5):462-471.
3. Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E. *Morb. Mortal. Wkly. Rep.* 2010; 59(10):299.
4. Hibbs RG, Weber JT, Corwin A, Allos BM, Abd el Rehim MS, Sharkawy SE, Sarn JE, and McKee KT Jr: Experience with the use of an investigational F(ab')₂ heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt. *Clin Infect Dis* 1996;23(2):337-340.
5. Richardson WH, Frei SS, and Williams SR: A case of type F botulism in southern California. *J Toxicol Clin Toxicol* 2004; 42(4):383-387.
6. Arnon SS: Creation and development of the public service orphan drug human botulism immune globulin. *Pediatrics* 2007;119(4):785-789.
7. Centers for Disease Control and Prevention: Centers for Disease Control and Prevention: Botulism in the United States, 1899-1996. Handbook for Epidemiologists, Clinicians, and Laboratory Workers, Atlanta, GA, 1998.
8. Lindstrom M, and Korkeala H: Laboratory diagnostics of botulism. *Clin Microbiol Rev* 2006;19(2):298-314.
9. Black JD, and Dolly JO: Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis. *J Cell Biol* 1986;103(2):535-544.
10. Black JD, and Dolly JO: Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves. *J Cell Biol* 1986;103(2):521-534.
11. Lacy DB, and Stevens RC: Sequence homology and structural analysis of the clostridial neurotoxins. *J Mol Biol* 1999;291(5):1091-1104.
12. Lacy DB, Tepp W, Cohen AC, DasGupta BR, and Stevens RC: Crystal structure of botulinum neurotoxin type A and implications for toxicity. *Nat Struct Biol* 1998;5(10):898-902.
13. Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, and Chapman ER: SV2 is the protein receptor for botulinum neurotoxin A. *Science* 2006;312(5773):592-596.
14. Rummel A, Eichner T, Weil T, Karnath T, Gutcaits A, Mahrhold S, Sandhoff K, Proia RL, Acharya KR, Bigalke H, and Binz T: Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept. *Proc Natl Acad Sci USA* 2007;104(1):359-364.
15. Montecucco C: How do tetanus and botulinum toxins bind to neuronal membranes? *Trends Biochem Sci* 1986;11(8):314-317.
16. Rummel A, Mahrhold S, Bigalke H, and Binz T: The H_{CC}-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction. *Mol Microbiol* 2004;51(3):631-643.
17. Swaminathan S, and Eswaramoorthy S: Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. *Nat Struct Biol* 2000;7(8):693-699.
18. Jin R, Rummel A, Binz T, and Brunger AT: Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity. *Nature* 2006;444(7122):1092-1095.
19. Ravichandran E, Al-Saleem FH, Ancharski DM, Elias MD, Singh AK, Shamim M, Gong Y, and Simpson LL: Trivalent vaccine against botulinum toxin serotypes A, B, and E that

- can be administered by the mucosal route. *Infect Immun* 2007;75(6):3043–3054.
20. Nowakowski A, Wang C, Powers DB, Amersdorfer P, Smith TJ, Montgomery VA, Sheridan R, Blake R, Smith LA, and Marks JD: Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. *Proc Natl Acad Sci USA* 2002;99(17):11346–11350.
 21. Pless DD, Torres ER, Reinke EK, and Bavari S: High-affinity, protective antibodies to the binding domain of botulinum neurotoxin type A. *Infect Immun* 2001;69(1):570–574.
 22. Baldwin MR, Tepp WH, Pier CL, Bradshaw M, Ho M, Wilson BA, Fritz RB, Johnson EA, and Barbieri JT: Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E. *Infect Immun* 2005;73(10):6998–7005.
 23. Boles J, West M, Montgomery V, Tammariello R, Pitt MLM, Gibbs P, Smith L, and LeClaire RD: Recombinant C fragment of botulinum neurotoxin B serotype (rBoNTB (H_C)) immune response and protection in the rhesus monkey. *Toxicon* 2006;47(8):877–884.
 24. Scotcher MC, Johnson EA, and Stanker LH: Characterization of the epitope region of F1-2 and F1-5, two monoclonal antibodies to botulinum neurotoxin type A. *Hybridoma* 2009;28(5):315–325.
 25. Wu H, Yeh C, Huang Y, Tarn L, and Lung C: Characterization of neutralizing antibodies and identification of neutralizing epitope mimics on the *Clostridium botulinum* neurotoxin Type A. *Appl Environ Microbiol* 2001;67(7):3201–3207.
 26. Yu R, Wang S, Yu Y, Du W, Yang F, Yu W, and Sun Z: Neutralizing antibodies of botulinum neurotoxin serotype a screened from a fully synthetic human antibody phage display library. *J Biomol Screen* 2009;14(8):991–998.
 27. Levy R, Forsyth CM, LaPorte SL, Geren IN, Smith LA, and Marks JD: Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display. *J Mol Biol* 2007;365(1):196–210.
 28. Stanker LH, Merrill P, Scotcher MC, and Cheng LW: Development and partial characterization of high-affinity monoclonal antibodies for botulinum toxin type A and their use in analysis of milk by sandwich ELISA. *J Immunol Methods* 2008;336(1):1–8.
 29. Marks JD: Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization. *Mov Disord* 2004;19(Suppl. 8).
 30. Cheng LW, Stanker LH, Henderson II TD, Lou J, and Marks JD: Antibody protection against botulinum neurotoxin intoxication in mice. *Infect Immun* 2009;77(10):4305–4313.
 31. Smith TJ, Lou J, Geren IN, Forsyth CM, Tsai R, LaPorte SL, Tepp WH, Bradshaw M, Johnson EA, Smith LA, and Marks JD: Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. *Infect Immun* 2005;73(9):5450–5457.
 32. Corbett CR, Elias MD, Simpson LL, Yuan X-, Cassan RR, Ballegeer E, Kabani A, Plummer FA, and Berry JD: High-throughput homogeneous immunoassay readily identifies monoclonal antibody to serovariant clostridial neurotoxins. *J Immunol Methods* 2007;328(1-2):128–138.
 33. Berry JD, Jones S, Drebot MA, Andonov A, Sabara M, Yuan XY, Weingartl H, Fernando L, Marszal P, Gren J, Nicolas B, Andonova M, Ranada F, Gubbins MJ, Ball TB, Kitching P, Li Y, Kabani A, and Plummer F: Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus. *J Virol Methods* 2004;120(1):87–96.
 34. Karlsson R, Michaelsson A, and Mattsson L: Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. *J Immunol Methods* 1991;145(1-2):229–240.
 35. Mabry R, Rani M, Geiger R, Hubbard GB, Carrion R Jr, Brasky K, Patterson JL, Georgiou G, and Iverson BL: Passive protection against anthrax by using a high-affinity antitoxin antibody fragment lacking an Fc region. *Infect Immun* 2005;73(12):8362–8368.
 36. Gubbins MJ, Berry JD, Corbett CR, Mogridge J, Yuan XY, Schmidt L, Nicolas B, Kabani A, and Tsang RS: Production and characterization of neutralizing monoclonal antibodies that recognize an epitope in domain 2 of *Bacillus anthracis* protective antigen. *FEMS Immunol Med Microbiol* 2006;47(3):436–443.
 37. Pearce LB, Borodic GE, First ER, and MacCallum RD: Measurement of botulinum toxin activity: evaluation of the lethality assay. *Toxicol Appl Pharmacol* 1994;128(1):69–77.
 38. Berry JD: Rational monoclonal antibody development to emerging pathogens, biothreat agents and agents of foreign animal disease: the antigen scale. *Vet J* 2005;170(2):193–211.
 39. Chen F, Kuziemko GM, Amersdorfer P, Wong C, Marks JD, and Stevens RC: Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms. *Infect Immun* 1997;65(5):1626–1630.
 40. Garcia-Rodriguez C, Levy R, Arndt JW, Forsyth CM, Razai A, Lou J, Geren I, Stevens RC, and Marks JD: Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. *Nat Biotechnol* 2007;25(1):107–116.
 41. Atassi MZ, and Dolimbek BZ: Mapping of the antibody-binding regions on the H_N-domain (residues 449-859) of botulinum neurotoxin A with antitoxin antibodies from four host species. Full profile of the continuous antigenic regions of the H-chain of botulinum neurotoxin A. *Protein J* 2004;23(1):39–52.
 42. Dolimbek BZ, Aoki KR, Steward LE, Jankovic J, and Atassi MZ: Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. *Mol Immunol* 2007;44(5):1029–1041.

Address correspondence to:

Dr. Cindi R. Corbett
National Microbiology Laboratory
1015 Arlington Street
Winnipeg, MB
Canada, R3E 3R2

E-mail: cindi.corbett@phac-aspc.gc.ca

Received: March 15, 2011

Accepted: August 4, 2011